These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 19224899)
1. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Pouladi MA; Graham RK; Karasinska JM; Xie Y; Santos RD; Petersén A; Hayden MR Brain; 2009 Apr; 132(Pt 4):919-32. PubMed ID: 19224899 [TBL] [Abstract][Full Text] [Related]
2. Weight loss in Huntington disease increases with higher CAG repeat number. Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372 [TBL] [Abstract][Full Text] [Related]
3. Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington's disease. Hult Lundh S; Nilsson N; Soylu R; Kirik D; Petersén Å Hum Mol Genet; 2013 Sep; 22(17):3485-97. PubMed ID: 23697793 [TBL] [Abstract][Full Text] [Related]
4. Caspase-6-Resistant Mutant Huntingtin Does not Rescue the Toxic Effects of Caspase-Cleavable Mutant Huntingtin in vivo. Graham RK; Deng Y; Pouladi MA; Vaid K; Ehrnhoefer D; Southwell AL; Bissada N; Franciosi S; Hayden MR J Huntingtons Dis; 2012; 1(2):243-60. PubMed ID: 25063333 [TBL] [Abstract][Full Text] [Related]
5. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Slow EJ; van Raamsdonk J; Rogers D; Coleman SH; Graham RK; Deng Y; Oh R; Bissada N; Hossain SM; Yang YZ; Li XJ; Simpson EM; Gutekunst CA; Leavitt BR; Hayden MR Hum Mol Genet; 2003 Jul; 12(13):1555-67. PubMed ID: 12812983 [TBL] [Abstract][Full Text] [Related]
6. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Graham RK; Slow EJ; Deng Y; Bissada N; Lu G; Pearson J; Shehadeh J; Leavitt BR; Raymond LA; Hayden MR Neurobiol Dis; 2006 Feb; 21(2):444-55. PubMed ID: 16230019 [TBL] [Abstract][Full Text] [Related]
7. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Morton AJ; Glynn D; Leavens W; Zheng Z; Faull RL; Skepper JN; Wight JM Neurobiol Dis; 2009 Mar; 33(3):331-41. PubMed ID: 19130884 [TBL] [Abstract][Full Text] [Related]
8. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236 [TBL] [Abstract][Full Text] [Related]
9. Selective degeneration in YAC mouse models of Huntington disease. Van Raamsdonk JM; Warby SC; Hayden MR Brain Res Bull; 2007 Apr; 72(2-3):124-31. PubMed ID: 17352936 [TBL] [Abstract][Full Text] [Related]
10. Effects of deletion of mutant huntingtin in steroidogenic factor 1 neurons on the psychiatric and metabolic phenotype in the BACHD mouse model of Huntington disease. Baldo B; Cheong RY; Petersén Å PLoS One; 2014; 9(10):e107691. PubMed ID: 25271967 [TBL] [Abstract][Full Text] [Related]
11. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin. Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600 [TBL] [Abstract][Full Text] [Related]
12. Expression of mutant huntingtin in leptin receptor-expressing neurons does not control the metabolic and psychiatric phenotype of the BACHD mouse. Lundh SH; Soylu R; Petersén A PLoS One; 2012; 7(12):e51168. PubMed ID: 23251447 [TBL] [Abstract][Full Text] [Related]
13. Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease. Garcia-Miralles M; Ooi J; Ferrari Bardile C; Tan LJ; George M; Drum CL; Lin RY; Hayden MR; Pouladi MA Exp Neurol; 2016 Apr; 278():4-10. PubMed ID: 26825854 [TBL] [Abstract][Full Text] [Related]
14. Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype. Hodgson JG; Smith DJ; McCutcheon K; Koide HB; Nishiyama K; Dinulos MB; Stevens ME; Bissada N; Nasir J; Kanazawa I; Disteche CM; Rubin EM; Hayden MR Hum Mol Genet; 1996 Dec; 5(12):1875-85. PubMed ID: 8968738 [TBL] [Abstract][Full Text] [Related]
15. [Clinical characteristics of Huntington disease in two pedigrees and analysis of expanded CAG trinucleotide repeat]. Cao GN; Bao XH; Lu HM; Zhang JJ; Ma YN; Gu WH; Xiong H; Qin J; Wu XR Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Apr; 43(2):163-7. PubMed ID: 21503105 [TBL] [Abstract][Full Text] [Related]
16. Viral vector mediated expression of mutant huntingtin in the dorsal raphe produces disease-related neuropathology but not depressive-like behaviors in wildtype mice. Pitzer M; Lueras J; Warden A; Weber S; McBride J Brain Res; 2015 May; 1608():177-90. PubMed ID: 25732261 [TBL] [Abstract][Full Text] [Related]
17. Huntington disease: clinical, genetic, and social aspects. Nance MA J Geriatr Psychiatry Neurol; 1998; 11(2):61-70. PubMed ID: 9877527 [TBL] [Abstract][Full Text] [Related]